Sign In
Buy APVO
$5.02
-0.0200 (-0.397%)
At Close: Jun 03, 2026
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D.
08:05am, Thursday, 28'th May 2026
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therape
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical Programs Innovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / A
All You Need to Know About Aptevo Therapeutics (APVO) Rating Upgrade to Buy
01:01pm, Wednesday, 20'th May 2026
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
08:05am, Wednesday, 13'th May 2026
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patients Executive leadership transition complete. Jeff Lamothe appointed CE
Program Enters Final Stage of Dose Optimization Data Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6,
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why
01:00pm, Friday, 10'th Apr 2026
Aptevo Therapeutics (APVO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aptevo Provides State of the Business Report and 2025 Financial Results
08:05am, Thursday, 26'th Mar 2026
Latest mipletamig data delivers 86% clinical benefit rate with no cytokine release syndrome in 28 frontline AML patients, supporting its potential to enhance standard-of-care combination therapy Compa
Aptevo to Participate in March 2026 Conferences
08:05am, Thursday, 19'th Mar 2026
SEATTLE, WA / ACCESS Newswire / March 19, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary A
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Decline in Short Interest
03:17am, Wednesday, 18'th Mar 2026
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
08:05am, Tuesday, 10'th Mar 2026
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo Therapeutic
Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Drop in Short Interest
02:15am, Monday, 16'th Feb 2026
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 152
Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
08:05am, Tuesday, 03'rd Feb 2026
Clinical progress, pipeline expansion, and operational momentum underpin leadership continuity as the Company advances into 2026 and beyond SEATTLE, WA / ACCESS Newswire / February 3, 2026 / Aptevo Th
Short Interest in Aptevo Therapeutics Inc. (NASDAQ:APVO) Drops By 86.5%
03:52am, Wednesday, 14'th Jan 2026
Aptevo Therapeutics Inc. (NASDAQ: APVO - Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,99
Together with cash on hand, the fully leveraged facility extends Aptevo's funding runway into 2029, enabling achievement of key clinical and preclinical milestones SEATTLE, WA / ACCESS Newswire / Janu
What's Going On With Aptevo Therapeutics Stock Today?
10:24am, Friday, 26'th Dec 2025
Shares of Aptevo Therapeutics Inc. (NASDAQ: APVO) are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.
